Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis

24 Nov 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous lymphoproliferative disorders research
Share to Histiocytic Disorders and Treatments
Share to Tuberous Sclerosis Complex Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 30474648
DOI: 10.1038/s41390-018-0238-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosisPMID 30474648Read ↗

BRAF-V600E–mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitorSemantic proximity Read ↗

Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis.Semantic proximity Read ↗

BRAF deletion in adult patients with Langerhans cell histiocytosis correlates with multisystem disease and poor outcomeSemantic proximity Read ↗

Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E.Semantic proximity Read ↗

Prevalence of the BRAF V600E mutation in Greek adults with Langerhans cell histiocytosis.Semantic proximity Read ↗

BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy.Semantic proximity Read ↗

BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.Semantic proximity Read ↗

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.Semantic proximity Read ↗

[Expression and clinical significance of BRAF V600E in children with Langerhans cell histiocytosis].Semantic proximity Read ↗

BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis.Semantic proximity Read ↗

Potential clinical implications of BRAF mutations in histiocytic proliferations.Semantic proximity Read ↗

The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.